College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China.
College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, China.
ACS Appl Mater Interfaces. 2022 Jun 29;14(25):28671-28682. doi: 10.1021/acsami.2c08587. Epub 2022 Jun 15.
Drug-based oncotherapy is seriously challenged by insufficient drug accumulation at tumor sites, mainly resulting from low drug loading efficiency and poor tumor-targeting ability of drug carriers. We herein proposed a "one-stone, two-bird" strategy to circumvent both obstacles, utilizing the source cancer cell membrane (CM) as a dual-function carrier to simultaneously achieve sufficient drug loading and homologous tumor targeting. Combining the use of TPGS (d-α-tocopherol polyethylene glycol 1000 succinate) to inhibit the drug efflux process of drug-resistant tumor, we constructed core-shell-structured nanocomposites CMGNPs consisting of ICG (indocyanine green)/DOX (doxorubicin)-loaded, TPGS/OA (oleic acid)-stabilized upconversion nanoparticles as the core and ICG-loaded MCF7/ADR CMs as the shell, for combined chemo/phototherapy of MCF7/ADR tumor. The employment of phospholipid bilayers of CMs as natural pockets for extra drug loading while preserving the homologous targeting ability greatly enhanced drug concentration at tumor sites, endowing CMGNPs with excellent therapeutic efficacy. Our effort provides a versatile approach for facilitating drug delivery in diverse therapeutic systems.
基于药物的肿瘤治疗受到肿瘤部位药物蓄积不足的严重挑战，主要是由于药物载体的载药效率低和肿瘤靶向能力差。我们在此提出了一种“一石二鸟”的策略来规避这两个障碍，利用源癌细胞膜（CM）作为双功能载体，同时实现充分的药物负载和同源肿瘤靶向。结合使用 TPGS（d-α-生育酚聚乙二醇 1000 琥珀酸）抑制耐药肿瘤的药物外排过程，我们构建了由 ICG（吲哚菁绿）/DOX（阿霉素）负载、TPGS/OA（油酸）稳定的上转换纳米粒子作为核和 ICG 负载的 MCF7/ADR CM 作为壳的核壳结构纳米复合材料 CMGNPs，用于 MCF7/ADR 肿瘤的联合化疗/光疗。CM 的磷脂双层作为额外药物负载的天然口袋的使用，同时保留了同源靶向能力，大大提高了肿瘤部位的药物浓度，赋予 CMGNPs 优异的治疗效果。我们的努力为促进各种治疗系统中的药物输送提供了一种通用方法。
